Clinical trials: Symptomatic COVID-19 Infection Laboratory-Confirmed
Adenovirus Infection, BK Virus Infection
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
This phase I trial tests the feasibility and safety of genetically modified cytotoxic T-lymphocytes in controlling infections caused by adenovirus (ADV), BK virus (BKV), cytomegalovirus (CMV), JC virus (JCV), or COVID-19 in…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT05101213
- Testing
- Virus-specific Cytotoxic T-lymphocytes
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza health-related outcomes of people with COVID-19 or influenza the effects of vaccines in people with COVID-19 or influenza.
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT06163677
- Testing
- COVID-19 Vaccine
- Sponsor
- Pfizer
Symptomatic COVID-19 Infection Laboratory-Confirmed
Dasatinib for the Treatment of Moderate and Severe COVID-19
This phase II trial investigates how well dasatinib works in treating patients with moderate and severe COVID-19. Dasatinib is a drug used to treat chronic leukemia which may help reduce the strong inflammation caused by COVID-19…
- Trial name
- NCT04830735
- Testing
- Dasatinib Anhydrous
- Where
- United States
- Sponsor
- University of Southern California
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization.
- Conditions
- Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis
- Trial name
- NCT04439006
- Testing
- Best Practice, Ibrutinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jennifer Woyach
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04379518
- Testing
- Recombinant Interferon Alfa-2b, Rintatolimod
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Roswell Park Cancer Institute
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
This phase I/II trial investigates the best dose and side effects of leflunomide and how well it works in treating patients with COVID-19 and a past or present cancer.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04532372
- Testing
- Best Practice, Leflunomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- City of Hope Medical Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Viral Specific T Cell Therapy for COVID-19 Related Pneumonia
This early phase I trial identifies the feasibility, possible benefits and/or side effects of administering SARS-CoV-2 specific cytotoxic T lymphocytes (CTLs) in treating cancer patients with severe acute respiratory syndrome…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04742595
- Testing
- SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with…
- Conditions
- COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04565665
- Testing
- Best Practice, Mesenchymal Stem Cell
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Symptomatic COVID-19 Infection Laboratory-Confirmed
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
This phase II trial studies the effect of baricitinib in combination with antiviral therapy for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19).
- Trial name
- NCT04373044
- Testing
- Baricitinib, Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Southern California
Pneumonia, Severe Acute Respiratory Syndrome
Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19
This phase III trial compares low dose whole lung radiation therapy to best supportive care plus physicians choice in treating patients with COVID-19 infection.
- Conditions
- Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- RESCUE1-19 (NCT04433949)
- Testing
- Best Practice, Low Dose Radiation Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
COVID-19, Infectious Disease
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
This is a first in human clinical study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RQ-01. Adult patients who have tested positive for SARS-CoV-2 virus, have mild symptom(s) of COVID-19 disease…
- Conditions
- COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
- Trial name
- NCT06063330
- Testing
- RQ-001
- Where
- 6 sites in United States
- Volunteers
- 66 people
- Sponsor
- Red Queen Therapeutics, Inc.
Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) is referred to as COVID-19 convalescent plasma (CCP), and may contain antibodies against SARS-CoV-2, the virus responsible for COVID-19.
- Trial name
- NCT04497779
- Testing
- Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Electronic Health Record Review
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
This phase II trial studies the effects of ibrutinib in treating patients with B-cell malignancies who are infected with COVID-19.
- Conditions
- Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT04665115
- Testing
- Ibrutinib, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Academic and Community Cancer Research United
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04455958
- Testing
- Lopinavir/Ritonavir, Questionnaire Administration
- Sponsor
- OHSU Knight Cancer Institute